IN RE HUMIRA (ADALIMUMAB) ANTITRUST LITIGATION

No. 19 CV 1873.

465 F.Supp.3d 811 (2020)

IN RE: HUMIRA (ADALIMUMAB) ANTITRUST LITIGATION.

United States District Court, N.D. Illinois, Eastern Division.

Signed June 8, 2020.


Attorney(s) appearing for the Case

Lauren G. Barnes , HAGENS BERMAN SOBOL SHAPIRO LLP, Cambridge MA, Karin E. Garvey , LABATON SUCHAROW LLP, New York, NY, Dena C. Sharp , GIRARD SHARP LLP, San Francisco, CA, for Plaintiffs.

Diana M. Watral , James F. Hurst , Damon C. Andrews , KIRKLAND & ELLIS LLP, Chicago, IL, for Defendants AbbVie, Inc & AbbVie Biotechnology Ltd.

Ian Simmons , Benjamin G. Bradshaw , Stephen J. McIntyre , Kurt C. Brown , Brian P. Quinn , Patrick Jones , O'MELVENY & MYERS LLP, Washington DC, Thomas B. Quinn , RILEY SAFER HOLMES & CANCILA LLP, Chicago, IL, for Defendant. Samsung Bioepis Co. Ltd.

Bruce R. Braun , David C. Giardina , Steven J. Horowitz , SIDLEY AUSTIN LLP, Chicago, IL, for Defendant Amgen Inc.

Stephen Weissman , Michael Perry , William Lavery , Christopher Wilson , Elisa Beneze , BAKER BOTTS LLP, Washington DC, for Defendant Sandoz, Inc.


MEMORANDUM OPINION AND ORDER

Defendant AbbVie Inc. makes a lot of money selling the prescription drug Humira. One reason for Humira's profitability is that AbbVie's Humira-related patents (more than a hundred) make it difficult (if not impossible) to sell competing drugs. Another reason may...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases